Careful implementation of PCSK9 inhibitors in clinical practice - PACE-CME

Careful implementation of PCSK inhibitors in clinical practice

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Possible approaches in precision medicine for secundary CV prevention
Possible approaches in precision medicine for secundary CV prevention
CSI 2016 ESC
Possible approaches in precision medicine for secundary CV prevention
- Dr. Noel Bairey Merz
Targeting residual inflammatory risk as a strategy to lower CV risk
Targeting residual inflammatory risk as a strategy to lower CV risk
CSI 2016 ESC
Targeting residual inflammatory risk as a strategy to lower CV risk
- prof. Paul Ridker, MD
What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?
What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?
CSI 2016 ESC
What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?
- Prof. Silvio E Inzucchi
Would lower than the current ApoB targets be more useful for clinical decision-making?
Would lower than the current ApoB targets be more useful for clinical decision-making?
CSI 2016 ESC
Would lower than the current ApoB targets be more useful for clinical decision-making?
- Seth Shay Martin, MD